Repository logo

Infoscience

  • English
  • French
Log In
Logo EPFL, École polytechnique fédérale de Lausanne

Infoscience

  • English
  • French
Log In
  1. Home
  2. Academic and Research Output
  3. Journal articles
  4. Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib
 
review article

Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib

Hantschel, Oliver  
•
Rix, Uwe
•
Superti-Furga, Giulio
2008
Leukemia & lymphoma

Following the initial success of imatinib as frontline therapy for chronic myeloid leukemia (CML), several second-generation therapeutics have been developed with increased potency and the ability to inhibit the majority of imatinib-resistant mutations. Here, we review the current knowledge about the target specificity of the two new inhibitors nilotinib and dasatinib in comparison to imatinib, including the recent large-scale chemical proteomics screens.

  • Details
  • Metrics
Type
review article
DOI
10.1080/10428190801896103
Author(s)
Hantschel, Oliver  
Rix, Uwe
Superti-Furga, Giulio
Date Issued

2008

Published in
Leukemia & lymphoma
Volume

49

Issue

4

Start page

615

End page

9

Editorial or Peer reviewed

REVIEWED

Written at

OTHER

EPFL units
UPHAN  
Available on Infoscience
March 21, 2011
Use this identifier to reference this record
https://infoscience.epfl.ch/handle/20.500.14299/65521
Logo EPFL, École polytechnique fédérale de Lausanne
  • Contact
  • infoscience@epfl.ch

  • Follow us on Facebook
  • Follow us on Instagram
  • Follow us on LinkedIn
  • Follow us on X
  • Follow us on Youtube
AccessibilityLegal noticePrivacy policyCookie settingsEnd User AgreementGet helpFeedback

Infoscience is a service managed and provided by the Library and IT Services of EPFL. © EPFL, tous droits réservés